Health-related quality of life of of women with breast cancer undergoing chemotherapy in the northern region of Brazil.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 92-92
Author(s):  
Namie Okino Sawada ◽  
Mary Elizabeth de Santana ◽  
Helena Megumi Sonobe

92 Background: In Brazil, the estimate for the year 2015 is approximately 576,000 new cases of cancer. Breast cancer is the most common in Brazilian women and the state of Pará is the first with the highest incidence of breast cancer in northern Brazil. The high incidence and changes caused by treatment and own illness as the disturbances in body image, functional, emotional and social changes cause fear in women, as well as disrupting daily activities and impact the health-Related Quality of Life (HRQOL). Improving HRQOL is an important goal so the evaluation of HRQoL of these patients is of interest to health professionals, as they provide information that help in planning treatment and rehabilitation. The objective is to evaluate the HRQoL of patients with breast cancer in chemotherapy treatment. Methods: It is a cross-sectional study with quantitative exploratory design. This place was a public hospital in the city of Belém do Pará, Women were included with breast cancer, over eighteen years old and excluded those with cognitive problems and metastases. The European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ C 30) and Questionnaire Breast Cancer Module (QLQ BR23) have been administrated. The project was approved by the Ethics Committee and were respected the resolution 466/2012 CNS / MS. Results: The sample consisted of 89 women with breast cancer undergoing chemotherapy, most in the age group over 40, mulatto, married, fundamental level of education, domestic load, Catholic religion, live in rural areas with incomes of one to two minimum salaries. The EORTC QLQ C 30 showed that the average QOL was 75.56, and the most impaired functions were physical (M = 65.62) and role performance (M = 58.61) and the most frequent symptoms were diarrhea, constipation, dyspnea, nausea and vomiting, fatigue, pain and loss of appetite. EORTC BR23 demonstrated functional scale (M = 49.95) and symptoms scale (M = 33.00). Conclusions: The results show that the side effects of chemotherapy affect the physical and functional function and consequently HRQoL of these patients.

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Diriba Alemayehu Gadisa ◽  
Esayas Tadesse Gebremariam ◽  
Getnet Yimer Ali

Abstract Background Breast cancer is the most common cancer among women and it affects quality of life of those women. So far, the two most frequently used tools for assessing health related quality of life in breast cancer patients, EORTC QLQ-C30 and EORTC QLQ-BR23 modules, were not validated in Ethiopia. Hence, the present study aimed to assess the psychometric properties of the tools among Ethiopian breast cancer patients. Methods Institutional based longitudinal study was conducted from January 1 to May 1, 2017 GC at only nationwide oncology center, Tikur Anbessa Specialized Hospital (TASH), Addis Ababa, Ethiopia. A total of 146 patients who visited the facility during that period, with no missing quality of life data, were selected for analysis. The psychometric properties of the EORTC QLQ-C30 and EORTC QLQ-BR23 were evaluated in terms of reliability, convergent, divergent, construct and clinical validity using SPSS version 22. Results Satisfactory internal consistency reliability (Cronbach’s α coefficients > 0.7) was confirmed, except for cognitive function (α = 0.516) of EORTC QLQ-C30 and body image (α = 0.510) of EORTC QLQ-BR23. Multiple-trait scaling analysis demonstrated a good convergent and divergent validity. No scaling errors were observed. Most items in EORTC QLQ-BR23 possessed a weak or no correlation with its own dimension in EORTC QLQ-C30 (r < 0.4) except with some of symptom scales. A statistically significant chemotherapy induced quality of life scores changes (P ≤ 0.05) were observed in all dimensions of both instruments between baseline and the end of first cycle chemotherapy, except for body image (P = 0.985) and sexual enjoyment (P = 0.817) of EORTC QLQ-BR23, indicating clinical validity. Conclusion Amharic version of the EORTC QLQ-C30 and EORTC QLQ-BR23 modules are valid and adequately reliable tool and can be used for clinical and epidemiological cancer researches to study the health related quality of life (HRQoL) of women with breast cancer in Ethiopia.


BMC Cancer ◽  
2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Maribel Salas ◽  
Margaret Mordin ◽  
Colleen Castro ◽  
Zahidul Islam ◽  
Nora Tu ◽  
...  

Abstract Background To identify and describe the breast cancer–specific health-related quality of life (HRQoL) instruments with evidence of validation in the breast cancer population for potential use in patients treated for breast cancer (excluding surgery). Methods We conducted a systematic literature review using PubMed, Embase, and PsycINFO databases to identify articles that contain psychometric properties of HRQoL instruments used in patients with breast cancer. Relevant literature from January 1, 2009, to August 19, 2019, was searched. Articles published in English that reported psychometric properties (reliability, validity) of HRQoL instruments were identified. Results The database search yielded 613 unique records; 131 full-text articles were reviewed; 80 articles presented psychometric data for instruments used in breast cancer (including generic measures). This article reviews the 33 full articles describing psychometric properties of breast cancer-specific HRQoL instruments: EORTC QLQ-C30, EORTC QLQ-BR23, FACT-B, FBSI, NFBSI-16, YW-BCI36, BCSS, QuEST-Br, QLICP-BR, INA-BCHRQoL, and two newly developed unnamed measures, one by Deshpande and colleagues (for use in India) and one by Vanlemmens and colleagues (for use among young women and their partners). The articles that described the EORTC QLQ-C30, QLQ-BR23, and FACT-B centered on validating translations, providing additional support for content validity, and demonstrating acceptability of electronic patient-reported outcome administration. Psychometric properties of the measures were acceptable. Several new measures have been developed in Asia with an emphasis on development on cultural relevance/sensitivity. Others focused on specific populations (i.e., young women with breast cancer). Conclusions Historically, there have been limited options for validated measures to assess HRQoL of patients with breast cancer. A number of new measures have been developed and validated, offering promising options for assessing HRQoL in this patient population. This review supports the reliability and validity of the EORTC QLQ-C30 and FACT-B; new translations and electronic versions of these measures further support their use for this population.


2018 ◽  
Vol 18 ◽  
pp. 153473541882044 ◽  
Author(s):  
Désirée Poier ◽  
Arndt Büssing ◽  
Daniela Rodrigues Recchia ◽  
Yvonne Beerenbrock ◽  
Marcus Reif ◽  
...  

Context: Cancer-related fatigue (CRF) is one of the most burdensome symptoms in breast cancer survivors (BCSs), accompanied by reduced health-related quality of life (HRQOL). Objectives: This study investigated the influence of a multimodal therapy (MT; psychoeducation, eurythmy therapy, painting therapy, and sleep education/restriction), or a combination therapy (CT; MT plus aerobic training [AT]) on HRQOL in BCS with chronic CRF in comparison with AT alone. Methods: One hundred and twenty-six BCSs with CRF were included in a pragmatic comprehensive cohort study and allocated either per randomization or by preference to MT, CT, or AT. The EORTC QLQ-C30 core questionnaire was used to measure HRQOL. All analyses on HRQOL parameters were done in an explorative intention. Results: Patients were assigned to MT (n = 44), CT (n = 54), or AT (n = 28). CT was significantly superior to AT after 10 weeks of intervention (T1) in improving physical function. MT was found to have significant superiority over AT at T1 and T2 for physical functioning, emotional functioning, insomnia, and financial problems as well as role functioning, cognitive, social functioning, and fatigue 6 months later (T2). Conclusion: A multimodal approach appears to be a suitable concept for BCS with chronic CRF. A confirmatory study with larger samples should demonstrate the superiority of MT and adapted CT in HRQOL compared with the current treatment AT found in these explorative analyses.


2004 ◽  
Vol 22 (16) ◽  
pp. 3381-3388 ◽  
Author(s):  
Fabio Efficace ◽  
Patrick Therasse ◽  
Martine J. Piccart ◽  
Corneel Coens ◽  
Kristel Van Steen ◽  
...  

Purpose The purpose of this research was to evaluate whether baseline health-related quality of life (HRQOL) parameters are prognostic factors for survival in locally advanced breast cancer patients. Although the literature highlights the important role of HRQOL parameters in predicting survival in advanced metastatic disease, little evidence exists for earlier stages. Patients and Methods The overall sample consisted of 448 patients randomly assigned to receive cyclophosphamide, epirubicin, and fluorouracil versus epirubicin, cyclophosphamide, and granulocyte colony-stimulating factor. Patients were enrolled in 12 countries. HRQOL baseline scores were assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30. The Cox proportional hazards regression model was used for both univariate and multivariate analyses of survival. In addition, a bootstrap resampling technique was used to assess the stability of the outcomes. Bootstrap results were then applied for model averaging purposes as a means to account for the observed model selection uncertainty. Results The final multivariate model retained inflammatory breast cancer (T4d) as the only factor predicting overall survival (OS) with a hazard ratio of 1.375 (95% CI, 1.027 to 1.840; P = .03). The presence of inflammatory breast cancer lowers the median survival time from 6.6 to 4.2 years (36% reduction). None of the preselected HRQOL variables were prognostic for OS or disease-free survival, in either the univariate or multivariate analysis. Conclusion Our findings suggest that baseline HRQOL parameters have no prognostic value in a nonmetastatic breast cancer population.


2021 ◽  
Author(s):  
Maribel Salas ◽  
Margaret Mordin ◽  
Colleen Castro ◽  
Zahidul Islam ◽  
Nora Tu ◽  
...  

Abstract Objective: To identify and describe the breast cancer–specific health-related quality of life (HRQoL) instruments with evidence of validation in the breast cancer population for potential use in patients treated for breast cancer (excluding surgery). Methods: We conducted a systematic literature review using PubMed, Embase, and PsycINFO databases to identify articles that contain psychometric properties of HRQoL instruments used in patients with breast cancer. Relevant literature from January 1, 2009, to August 19, 2019, was searched. Articles published in English that reported psychometric properties (reliability, validity) of HRQoL instruments were identified.Results: The database search yielded 613 unique records; 131 full-text articles were reviewed; 80 articles presented psychometric data for instruments used in breast cancer. This article focuses on the 33 that described psychometric properties of breast cancer–specific HRQoL instruments. Twelve breast cancer–specific HRQoL instruments were identified and reviewed: EORTC QLQ-C30, EORTC QLQ-BR23, FACT-B, FBSI, NFBSI-16, YW-BCI36, BCSS, QuEST-Br, QLICP-BR, INA-BCHRQoL, and two newly developed unnamed measures, one by Deshpande and colleagues (for use in India) and one by Vanlemmens and colleagues (for use among young women and their partners). The articles that described the EORTC QLQ-C30, QLQ-BR23, and FACT-B centered on validating translations, providing additional support for content validity, and demonstrating acceptability of electronic patient-reported outcome administration. Psychometric properties of the measures were acceptable. Several new measures have been developed in Asia with an emphasis on development on cultural relevance/sensitivity. Others focused on specific populations (i.e., young women with breast cancer). Conclusions: Historically, there have been limited options for validated measures to assess HRQoL of patients with breast cancer. A number of new measures have been developed and validated, offering promising options for assessing HRQoL in this patient population. This review supports the reliability and validity of the EORTC QLQ-C30 and FACT-B; new translations and electronic versions of these measures further support their use for this population.


2012 ◽  
Vol 21 (5) ◽  
pp. 684-691 ◽  
Author(s):  
O. CEREZO ◽  
L.F. OÑATE-OCAÑA ◽  
P. ARRIETA-JOFFE ◽  
F. GONZÁLEZ-LARA ◽  
M.J. GARCÍA-PASQUEL ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document